Type 2 diabetes mellitus and cardiovascular disease: Genetic and epigenetic links

Frontiers in Endocrinology

Volumn 9, Issue JAN, 2018, Pages

  De Rosa, Salvatore ^a   Arcidiacono, Biagio ^a   Chiefari, Eusebio ^a   Brunetti, Antonio ^a   Indolfi, Ciro ^a   Foti, Daniela P ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cardiovascular disease; Epigenetics; Genetic polymorphisms; High mobility group A1 variant; Type 2 diabetes mellitus

Indexed keywords

HIGH MOBILITY GROUP A PROTEIN; LONG UNTRANSLATED RNA; MICRORNA;

CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DNA MODIFICATION; EPIGENETICS; GENE LOCUS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; HEART INFARCTION; HISTONE MODIFICATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; REVIEW;

EID: 85041105104     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2018.00002     Document Type: Review

References (190)

1. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet (2005) 9467:1333-46. doi:10.1016/S0140-6736(05)61032-X
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 27:1047-53. doi:10.2337/diacare.27.10.2569-a
3. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med (2007) 356:213-5. doi:10.1056/NEJMp068177
4. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract (2014) 103:137-49. doi:10.1016/j.diabres.2013.11.002
5. Krolewski AS, Warram JH, Freire MB. Epidemiology of late diabetic complications. A basis for the development and evaluation of preventive programs. Endocrinol Metab Clin North Am (1996) 2:217-42. doi:10.1016/S0889-8529(05)70322-4
6. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation (2017) 135:e146-603. doi:10.1161/CIR.0000000000000485
7. Kannel WB, McGee DL. Diabetes and cardiovascular disease. JAMA (1979) 241:2035-8. doi:10.1001/jama.1979.03290450033020
8. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for health professionals from the American Heart Association. Circulation (1999) 100:1134-46. doi:10.1161/01.CIR.100.10.1134
9. Kim JA, Koh KK, Quon MJ. The union of vascular and metabolic actions of insulin in sickness and in health. Arterioscler Thromb Vasc Biol (2005) 25(5):889-91. doi:10.1161/01.ATV.0000164044.42910.6b
10. Woods M, Mitchell JA, Wood EG, Barker S, Walcot NR, Rees GM, et al. Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. Mol Pharmacol (1999) 55:902-9
11. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med (2004) 350:664-71. doi:10.1056/NEJMoa031314
12. Low Wang CC, Hess CN, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus-mechanisms, management, and clinical considerations. Circulation (2016) 133:24. doi:10.1161/CIRCULATIONAHA.116.022194
13. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications (2001) 15:44-54. doi:10.1016/S1056-8727(00)00132-X
14. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med (1999) 340:115-26. doi:10.1056/NEJM199901143400207
15. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA (1990) 263:2893-8. doi:10.1001/jama.263.21.2893
16. Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation (2000) 102:42-7. doi:10.1161/01.CIR.102.1.42
17. Otani H. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome. Antioxid Redox Signal (2011) 15:1911-26. doi:10.1089/ars.2010.3739
18. Andreotti F, Becker RC. Atherothrombotic disorders: new insights from hematology. Circulation (2005) 111:1855-63. doi:10.1161/01.CIR.0000160361.73423.23
19. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension (2001) 37:1053-9. doi:10.1161/01.HYP.37.4.1053
20. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes (1995) 44:369-74. doi:10.2337/diabetes.44.4.369
21. Wu L, Parhofer KG. Diabetic dyslipidemia. Metabolism (2014) 63:1469-79. doi:10.1016/j.metabol.2014.08.010
22. Wilson PW, Kannel WB. Obesity, diabetes, and risk of cardiovascular disease in the elderly. Am J Geriatr Cardiol (2002) 11:119-23. doi:10.1111/j.1076-7460.2002.00998.x
23. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol (2012) 59:7. doi:10.1016/j.jacc.2011.08.080
24. Greco M, Chiefari E, Montalcini T, Accattato F, Costanzo FS, Pujia A, et al. Early effects of a hypocaloric, Mediterranean diet on laboratory parameters in obese individuals. Mediators Inflamm (2014) 2014:750860. doi:10.1155/2014/750860
25. Ma RCW. Genetics of cardiovascular and renal complications in diabetes. J Diabetes Investig (2016) 7:139-54. doi:10.1111/jdi.12391
26. Chiefari E, Tanyolaç S, Paonessa F, Pullinger CR, Capula C, Iiritano S, et al. Functional variants of the HMGA1 gene and type 2 diabetes mellitus. JAMA (2011) 305:9. doi:10.1001/jama.2011.207
27. De Rosa S, Chiefari E, Salerno N, Ventura V, D'Ascoli GL, Arcidiacono B, et al. HMGA1 is a novel candidate gene for myocardial infarction susceptibility. Int J Cardiol (2017) 227:331-4. doi:10.1016/j.ijcard.2016.11.088
28. De Rosa S, Curcio A, IndolfiC. Emerging role of microRNAs in cardiovascular diseases. Circ J (2014) 78:567-75. doi:10.1253/circj. CJ-14-0086
29. Gareri C, De Rosa S, IndolfiC. MicroRNAs for restenosis and thrombosis after vascular injury. Circ Res (2016) 118:1170-84. doi:10.1161/CIRCRESAHA.115.308237
30. Iaconetti C, Gareri C, Polimeni A, IndolfiC. Non-coding RNAs: the "dark matter" of cardiovascular pathophysiology. Int J Mol Sci (2013) 14:19987-20018. doi:10.3390/ijms141019987
31. American Diabetes Association. Standards of medical care in diabetes-2017, classification and diagnosis of diabetes. Diabetes Care (2017) 40:S11-24. doi:10.2337/dc17-S005
32. O'Donnell CJ, Nabel EG. Genomics of cardiovascular disease. N Engl J Med (2011) 365:2098-109. doi:10.1056/NEJMra1105239
33. Besseling J, Kastelein JJ, Defesche JC, Hutten BA, Hovingh GK. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA (2015) 313:1029-36. doi:10.1001/jama.2015.1206
34. Mohlke KL, Boehnke M, Abecasis GR. Metabolic and cardiovascular traits: an abundance of recently identified common genetic variants. Hum Mol Genet (2008) 17(R2):R102-8. doi:10.1093/hmg/ddn275
35. Kathiresan S, Srivastava D. Genetics of human cardiovascular disease. Cell (2012) 148:1242-57. doi:10.1016/j.cell.2012.03.001
36. Wang X, Strizivh G, Hu Y, Wang T, Kaplan RC, Qi Q. Genetic markers of type 2 diabetes: progress in genome-wide association studies and clinical application for risk prediction. J Diabetes (2016) 8:24-35. doi:10.1111/1753-0407.12323
37. Ashar FN, Arking DE. Genomics of complex cardiovascular disease. 2nd ed. In: Kumar D, Eng C, editors. Genomic Medicine: Principles and Practice. New York, NY: Oxford University Press (2014). p. 316-36
38. Bacci S, Menzaghi C, Ercolino T, Ma X, Rauseo A, Salvemini L, et al. The +276 G/T single nucleotide polymorphism of the adiponectin gene is associated with coronary artery disease in type 2 diabetic patients. Diabetes Care (2004) 27:2015-20. doi:10.2337/diacare.27.8.2015
39. Soccio T, Zhang YY, Bacci S, Mlynarski W, Placha G, Raggio G, et al. Common haplotypes at the adiponectin receptor 1 (ADIPOR1) locus are associated with increased risk of coronary artery disease in type 2 diabetes. Diabetes (2006) 55(2763):2770. doi:10.2337/db06-0613
40. Sousa AG, Selvatici L, Krieger JE, Pereira AC. Association between genetics of diabetes, coronary artery disease, and macrovascular complications: exploring a common ground hypothesis. Rev Diabet Stud (2011) 8:230-44. doi:10.1900/RDS.2011.8.230
41. Ukkola O, Kervinen K, Salmela PI, von DickhoffK, Laakso M, Kesaniemi YA. Apolipoprotein E phenotype is related to macro-and microangiopathy in patients with non-insuli dependent diabetes mellitus. Atherosclerosis (1993) 101:9-15. doi:10.1016/0021-9150(93)90096-D
42. El-Lebedy D, Raslan HM, Mohammed AM. Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular disease. Cardiovasc Diabetol (2016) 15:12. doi:10.1186/s12933-016-0329-1
43. Qi L, Parast L, Cai T, Powers C, Gervino EV, Hauser TH, et al. Genetic susceptibility to coronary heart disease in type 2 diabetes: 3 independent studies. J Am Coll Cardiol (2011) 58:2675-82. doi:10.1016/j.jacc.2011.08.054
44. Qi L, Qi Q, Prudente S, Mendonca C, Andreozzi F, di Pietro N, et al. Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes. JAMA (2013) 310:821-8. doi:10.1001/jama.2013.276305
45. Beaney KE, Cooper JA, McLachlan S, Wannamethee SG, Jefferis BJ, Whincup P, et al. Variant rs10911021 that associates with coronary heart disease in type 2 diabetes, is associated with lower concentrations of circulating HDL cholesterol and large HDL particle but not with amino acids. Cardiovasc Diabetol (2016) 15:115. doi:10.1186/s12933-016-0435-0
46. Levy AP. Haptoglobin: a major susceptibility gene for diabetic cardiovascular disease. Isr Med Assoc J (2004) 6:308-10
47. Adams JN, Cox AJ, Freedman BI, Langefeld C, Carr JJ, Bowden DW. Genetic analysis of haptoglobin polymorphisms with cardiovascular disease and type 2 diabetes in the diabetes heart study. Cardiovasc Diabetol (2013) 12:31. doi:10.1186/1475-2840-12-31
48. Ruiz J, Blanché H, James RW, Garin MC, Vaisse C, Charpentier G, et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet (1995) 346:869-72. doi:10.1016/S0140-6736(95)92709-3
49. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest (1995) 96:30005-8. doi:10.1172/JCI118373
50. Blatter Garin MC, James P, Blanché H, Passa P, Froguel P, Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentration of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease. J Clin Invest (1997) 99:62-6. doi:10.1172/JCI119134
51. Pfohl M, Koch M, Enderle MD, Kuehn R, Fuellhase J, Karsch KR, et al. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes (1999) 48:623-7. doi:10.2337/diabetes.48.3.623
52. Jones DA, Prior SL, Tang TS, Bain SC, Hurel SJ, Humphries SE, et al. Association between the rs4880 superoxide dismutase 2(C > T) gene variant and coronary heart disease in diabetes mellitus. Diabetes Res Clin Pract (2010) 90:196-201. doi:10.1016/j.diabres.2010.07.009
53. Sousa AG, Marquezine GF, Lemos PA, Martinez E, Lopes N, Hueb WA, et al. TCF7L2 polymorphism rs7903146 is associated with coronary artery disease severity and mortality. PLoS One (2009) 11:e7697. doi:10.1371/journal.pone.0007697
54. Muendlein A, Saely CH, Geller-Rhomberg S, Sonde-Regger G, Rein P, Winder T, et al. Single nucleotide polymorphisms of TCF7L2 are linked to diabetic coronary atherosclerosis. PLoS One (2011) 3:e17978. doi:10.1371/journal.pone.0017978
55. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res (2010) 107:1058-70. doi:10.1161/CIRCRESAHA.110223545
56. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J (2009) 74:608-14. doi:10.1253/circj. CJ-09-0057
57. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes (2005) 54:534-9. doi:10.2337/diabetes.54.2.534
58. Wellcome Trust Case Control Consortium. Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. Nature (2007) 447:661-78. doi:10.1038/nature05911
59. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science (2007) 316:1491-3. doi:10.1126/science.1142842
60. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 316:1331-6. doi:10.1126/science.1142358
61. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science (2007) 316:1341-5. doi:10.1126/science.1142382
62. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliot KS, Lango H, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science (2007) 316:1336-41. doi:10.1126/science.1142364
63. Li Z, Yu X, Shen J. ANRIL: a pivotal tumor suppressor long non-coding RNA in human cancers. Tumour Biol (2016) 37:5657-61. doi:10.1007/s13277-016-4808-5
64. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature (2007) 445:881-5. doi:10.1038/nature05616
65. Salonen JT, Uimari P, Aalto JM, Pirskanen M, Kaikkonen J, Tdorova B, et al. Type 2 diabetes whole-genome association study in four populations: the DiaGen consortium. Am J Hum Genet (2007) 81:338-45. doi:10.1086/520599
66. Broadbent HM, Peden JF, Lorkowski S, Goel A, Ongen H, Green F, et al. Susceptibility to coronary heart disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet (2008) 17:806-14. doi:10.1093/hmg/ddm352
67. Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature (2010) 464:409-12. doi:10.1038/nature08801
68. Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B. Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL expression. PLoS Genet (2010) 6:e1000899. doi:10.1371/journal.pgen.1000899
69. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Hentzman N, et al. 9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature (2011) 470:264-8. doi:10.1038/nature09753
70. Jarinova O, Stewart AF, Roberts R, Wells G, Lau P, Naing T, et al. Functional analysis of the chromosome 9p21.3 coronary artery diseaes risk locus. Arterioscler Thromb Vasc Biol (2009) 29:1671-7. doi:10.1161/ATVBAHA.109.189522
71. Bantubungi K, Hannou SA, Caron-Houde S, Vallez E, Baron M, Lucas A, et al. Cdkn2a/p16Ink4a regulates fasting-induced hepatic gluconeogenesis through the PKA-CREB-PGC1a pathway. Diabetes (2014) 63:3199-209. doi:10.2337/db13-1921
72. Holdt LM, Hoffmann S, Sass K, Langenberger D, Scholz M, Krohn K, et al. Alu elements in ANRIL non-coding RNA at chromosome 9p21 modulate atherogenic cell functions through trans-regulation of gene networks. PLoS Genet (2013) 9:e1003588. doi:10.1371/journal.pgen.1003588
73. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet (2006) 38:320-3. doi:10.1038/ng1732
74. Bielinski SJ, Pankow JS, Folsom AR, North KE, Boerwinkle E. TCF7L2 single nucleotide polymorphisms, cardiovascular disease and all-cause mortality: the atherosclerosis risk in communities (ARIC) study. Diabetologia (2008) 6:968-70. doi:10.1007/s00125-008-1004-1
75. Vendrell J, Fernandez-Real JM, Gutierrez C, Zamora A, Simon I, Bardaji A, et al. A polymorphism in the promoter of the tumor necrosis factor-alpha gene (-308) is associated with coronary heart diseaes in type 2 diabetic patients. Atherosclerosis (2003) 167:257-64. doi:10.1016/S0021-9150(02)00429-X
76. Asleh R, Marsch S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res (2003) 92:1193-200. doi:10.1161/01.RES.0000076889.23082.F1
77. Bowden DW, Cox AJ. Diabetes: unravelling the enigma of type 2 DM and cardiovascular disease. Nat Rev Endocrinol (2013) 9:632-3. doi:10.1038/nrendo.2013.192
78. Chan KHK, Huang YT, Meng Q, Wu C, Reiner A, Sobel EM, et al. Shared molecular pathways and gene networks for cardiovascular disease and type 2 diabetes mellitus in women across diverse ethnicities. Circ Cardiovasc Genet (2014) 7:911-9. doi:10.1161/CIRCGENETICS.114.000676
79. Qi Q, Meigs JB, Rexrode KM, Hu FB, Qi L. Diabetes genetic predisposition score and cardiovascular complications among patients with type 2 diabetes. Diabetes Care (2013) 36:737-9. doi:10.2337/dc12-0852
80. Pfister R, Barnes D, Luben RN, Khaw KT, Wareham NJ, Langenberg C. Individual and cumulative effect of type 2 diabetes genetic susceptibility variants on risk of coronary heart disease. Diabetologia (2011) 54:2283-7. doi:10.1007/s00125-011-2206-5
81. Cox AJ, Hsu FC, Ng MC, Langefeld CD, Freedman BI, Carr JJ, et al. Genetic risk score associations with cardiovascular disease and mortality in the diabetes heart study. Diabetes Care (2014) 37:1157-64. doi:10.2337/dc13-1514
82. Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene (2001) 277:63-81. doi:10.1016/S0378-1119(01)00689-8
83. Sgarra R, Zammitti S, Lo Sardo A, Maurizio E, Arnoldo L, Pegoraro S, et al. HMGA molecular network: from transcriptional regulation to chromatin remodeling. Biochim Biophys Acta (2010) 1799:37-47. doi:10.1016/j.bbagrm.2009.08.009
84. Schuldenfrei A, Belton A, Kowalski J, Talbot CC Jr, Di Cello F, Poh W, et al. HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis. BMC Genomics (2011) 12:539. doi:10.1186/1471-2164-12-549
85. Yie J, Merika M, Munshi N, Chen G, Thanos D. The role of HMG I(Y) in the assembly and function of the IFN-beta enhanceosome. EMBO J (1999) 18:3074-89. doi:10.1093/emboj/18.11.3074
86. Arnoldo L, Sgarra R, Chiefari E, Iiritano S, Arcidiacono B, Pegoraro S, et al. A novel mechanism of post-translational modulation of HMGA1 functions by the histone chaperone nucleophosmin. Sci Rep (2015) 5:8552. doi:10.1038/srep08552
87. Paonessa F, Foti D, Costa V, Chiefari E, Leone F, Luciano F, et al. Activator protein-2 overexpression accounts for increased insulin receptor expression in human breast cancer. Cancer Res (2006) 10:5085-93. doi:10.1158/0008-5472.CAN-05-3678
88. Foti D, Iuliano R, Chiefari E, Brunetti A. A nucleoprotein complex containing Sp1, C/EBP beta, and HMGI-Y controls human insulin receptor gene expression. Mol Cell Biol (2003) 23:2720-32. doi:10.1128/MCB.23.8.2720-2732.2003
89. Costa V, Foti D, Paonessa F, Chiefari E, Palaia L, Brunetti G, et al. The insulin receptor: a new nticancer target for peroxisome proliferator-activated receptor-gamma (PPARgamma) and thiazolidinedione-PPARgamma agonists. Endocr Relat Cancer (2008) 15:325-35. doi:10.1677/ERC-07-0226
90. Iiritano S, Chiefari E, Ventura V, Arcidiacono B, Possidente K, Nocera A, et al. The HMGA1-IGF-I/IGFBP system: a novel pathway for modulating glucose uptake. Mol Endocrinol (2012) 6:1578-89. doi:10.1210/me.2011-1379
91. Bianconcini A, Lupo A, Capone S, Quadro L, Monti M, Zurlo D, et al. Transcriptional activity of the murine retinol-binding protein gene is regulated by a multiprotein complex containing HMGA1, p54 nrb/NonO, protein-associated splicing factor (PSF) and steroidogenic factor 1 (SF1)/liver receptor homologue 1 (LHR-1). Int J Biochem Cell Biol (2009) 41:2189-203. doi:10.1016/j.biocel.2009.04.011
92. Messineo S, Laria AE, Arcidiacono B, Chiefari E, Luque Huertas RM, Foti DP, et al. Cooperation between HMGA1 and HIF-1 contributes to hypoxia-induced VEGF and visfatin gene expression in 3T3-L1 adipocytes. Front Endocrinol (2016) 7:73. doi:10.3389/fendo2016.00073
93. Arcidiacono B, Iiritano S, Chiefari E, Brunetti FS, Gu G, Foti DP, et al. Cooperation between HMGA1, PDX-1, and MafA is essential for glucose-induced insulin transcription in pancreatic beta cells. Front Endocrinol (2015) 5:237. doi:10.3389/fendo.2014.00237
94. Chiefari E, Nevolo MT, Arcidiacono B, Maurizio E, Nocera A, Iiritano S, et al. HMGA1 is a novel downstream nuclear target of the insulin recptor signaling pathway. Sci Rep (2012) 2:251. doi:10.1038/srep00251
95. Foti D, Chiefari E, Fedele M, Iuliano R, Brunetti L, Paonessa F, et al. Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in human and mice. Nat Med (2005) 7:765-73. doi:10.1038/nm1254
96. Chiefari E, Iiritano S, Paonessa F, Le Pera I, Arcidiacono B, Filocamo M, et al. Pseudogene-mediated posttranscriptional silencing of HMGA1 can result in insulin resistance and type 2 diabetes. Nat Commun (2010) 1:40. doi:10.1038/ncomms1040
97. Pullinger CR, Goldfine ID, Tanyolaç S, Movsesyan I, Faynboym M, Durlach V, et al. Evidence that an HMGA1 gene variant associates with type 2 diabetes, body mass index, and high-density lipoprotein cholesterol in a Hispanic-American population. Metab Syndr Relat Disord (2014) 12:1. doi:10.1089/met.2013.0086
98. Bianco A, Chiefari E, Nobile CG, Foti D, Pavia M, Brunetti A. The association between HMGA1 rs146052672 variant and type 2 diabetes: a transethnic meta-analysis. PLoS One (2015) 10:8. doi:10.1371/journal.pone.0136077
99. Chiefari E, Tanyolaç S, Iiritano S, Sciacqua A, Capula C, Arcidiacono B, et al. A polymorphism of HMGA1 is associated with increased risk of metabolic syndrome and related components. Sci Rep (2013) 3:1491. doi:10.1038/srep01491
100. Melillo RM, Pierantoni GM, Scala S, Battista S, Fedele M, Stella A, et al. Critical role of the HMGI(Y) proteins in adipocytic cell growth and differentiation. Mol Cell Biol (2001) 21:2485-95. doi:10.1128/MCB.21.7.2485-2495.2001
101. Arce-Cerezo A, Garcia M, Rodriguez-Nuevo A, Crosa-Bonell M, Enguix N, Pero A, et al. HMGA1 overexpression in adiose tissue impairs adipogenesis and prevents diet-induced obesity and insulin resistance. Sci Rep (2015) 5:14487. doi:10.1038/srep14487
102. TreffNR, Pouchnik D, Dement GA, Britt RL, Reeves R. High-mobility group A1a protein regulates Ras/ERK signaling in MCF-7 human breast cancer cells. Oncogene (2004) 23:777-85. doi:10.1038/sj.onc.1207167
103. Foster LC, Wiesel P, Huggins GS, Pañares R, Chin MT, Pellacani A, et al. Role of activating protein-1 and high mobility group-I(Y) protein in the induction of CD44 gene expression by interleukin-1beta in vascular smooth muscle cells. FASEB J (2000) 14:368-78
104. Schlueter C, Hauke S, Loeschke S, Wenk HH, Bullerdiek J. HMGA1 proteins in human atherosclerotic plaques. Pathol Res Pract (2005) 201:101-7. doi:10.1016/j.prp.2004.11.010
105. Bloch M, Prock A, Paonessa F, Benz V, Baehr IN, Herbst L, et al. High-mobility group A1 protein: a new coregulator of peroxisome proliferator-activated receptor-gamma mediated transrepression in the vasculature. Circ Res (2012) 110:394-405. doi:10.1161/CIRCRESAHA.111.253658
106. Chiefari E, Ventura V, Capula C, Randazzo G, Scorcia V, Fedele M, et al. A polymorphism of HMGA1 protects against proliferative diabetic retinopathy by impairing HMGA1-induced VEGFA expression. Sci Rep (2016) 6:39429. doi:10.1038/srep39429
107. Shanmugam N, Reddy MA, Guha M, Natarajam R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes (2003) 52:1256-64. doi:10.2337/diabetes.52.5.1256
108. Ceriello A. The emerging challenge in diabetes: the "metabolic memory". Vascul Pharmacol (2012) 57:133-8. doi:10.1016/vph.2012.05.005
109. Pirola L, Balcerczyk A, Tothill RW, Haviv I, Kaspi A, Lunke S, et al. Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells. Genome Res (2011) 21(10):1601-15. doi:10.1101/gr.116095.110
110. Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK, et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes (2009) 58:1229-36. doi:10.2337/db08-1666
111. Keating S, Plutzky J, El-Osta A. Epigenetic changes in diabetic and cardiovascular risk. Circ Res (2016) 118:1706-22. doi:10.1161/CIRCRESAHA.116.306819
112. Paneni F, Volpe M, Lüscher TF, Cosentino F. SIRT1, p66(Shc), and Set7/9 in vascular hyperglycemic memory: bringing all the strands together. Diabetes (2013) 62:1800-7. doi:10.2337/db12-1648
113. Aslibekyan S, Class SA, Arnett DK. Clinical applications of epigenetics in cardiovascular disease: the long road ahead. Transl Res (2015) 165:143-53. doi:10.1016/j.trsl.2014.04.004
114. Sathiskumar C, Prabu P, Balakumar M, Lenin R, Prabhu D, Anjana RM, et al. Augmentation of histone deacetylase 3 (HDAC3) epigenetic signature at the interface of proinflammation and insulin resistance in patients with type 2 diabetes. Clin Epigenetics (2016) 8:125. doi:10.1186/s13148-016-0293-3
115. Bell CG, Finer S, Lindgren CM, Wilson GA, Rakyan VK, TeschendorffAE, et al. Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the FTO type 2 diabetes and obesity susceptibility locus. PLoS One (2010) 5:e14040. doi:10.1371/journal.pone.0014040
116. Liu C, Mou S, Pan C. The FTO gene rs9939609 polymorphism predict risk of cardiovascular disease: a systematic review and metanalysis. PLoS One (2013) 8:e71901. doi:10.1371/journal.pone.0071901
117. Deodati A, Inzaghi E, Liguori A, Puglianiello A, Germani D, Brufani C, et al. IGF2 methylation is associated with lipid profile in obese children. Horm Res Paediatr (2013) 79:361-7. doi:10.1159/000351707
118. Arner P, Sahlqvist AS, Sinha I, Xu H, Yao X, Waterworth D, et al. The epigenetic signature of systemic insulin resistance in obese women. Diabetologia (2016) 59:2393-405. doi:10.1007/s00125-016-4074-5
119. Nilsson E, Jansson PA, Perfilyev A, Volkov P, Pedersen M, Svensson MK, et al. Altered DNA methylation and differential expression of genes influencing metabolism and inflammation in adipose tissue from subjects with type 2 diabetes. Diabetes (2014) 63:2962-76. doi:10.2337/db13-1459
120. Rönn T, Volkov P, Gillberg L, Kokosar M, Perfilyev A, Jacobsen AL, et al. Impact of age, BMI and HbA1c levels on the genome-wide DNA methylation and mRNA expression patterns in human adipose tissue and identification of epigenetic biomarkers in blood. Hum Mol Genet (2015) 24:3792-813. doi:10.1093/hmg/ddv124
121. Benton MC, Johnstone A, Eccles D, Harmon B, Hayes MT, Lea RA, et al. An analysis of DNAmethylation in human adipose tissue reveals differential modification of obesity genes before and after gastric bypass and weight loss. Genome Biol (2015) 16:8. doi:10.1186/s13059-014-0569-x
122. Yang X, Wang X, Liu D, Yu L, Xue B, Shi H. Epigenetic regulation of macrophage polarization by DNAmethyltransferase 3b. Mol Endocrinol (2014) 28:565-74. doi:10.1210/me.2013-1293
123. Talens RP, Jukema JW, Trompet S, Kremer D, Westendorp RG, Lumey LH, et al. Hypermethylation at loci sensitive to the prenatal environment is associated with increased incidence of myocardial infarction. Int J Epidemiol (2012) 41:106-15. doi:10.1093/ije/dyr153
124. Romaine SP, Tomaszewski M, Condorelli G, Samani NJ. MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart (2015) 101:921-8. doi:10.1136/heartjnl-2013-305402
125. Hashimoto N, Tanaka T. Role of miRNAs in the pathogenesis and susceptibility of diabetes mellitus. J Hum Genet (2017) 62:141-50. doi:10.1038/jhg.2016.150
126. Kwak SH, Park KS. Recent progress in genetic and epigenetic research on type 2 diabetes. Exp Mol Med (2016) 48:e220. doi:10.1038/emm.2016.7
127. Ding Y, Sun X, Shan PF. MicroRNAs and cardiovascular disease in diabetes mellitus. Biomed Res Int (2017) 2017:4080364. doi:10.1155/2017/4080364
128. Diao X, Shen E, Wang X, Hu B. Differentially expressed microRNAs and their target genes in the hearts of streptozotocin-induced diabetic mice. Mol Med Rep (2011) 4:633-40. doi:10.3892/mmr.2011.489
129. La Sala L, Cattaneo M, De Nigris V, Pujadas G, Testa R, Bonfigli AR, et al. Oscillating glucose induces microRNA-185 and impairs an efficient antioxidant response in human endothelial cells. Cardiovasc Diabetol (2016) 15:71. doi:10.1186/s12933-016-0390-9
130. Arunachalam G, Lakshmanan AP, Samuel SM, Triggle CR, Ding H. Molecular interplay between microRNA-34a and sirtuin1 in hyperglycemia-mediated impaired angiogenesis in endothelial cells: effects of metformin. J Pharmacol Exp Ther (2016) 356:314-23. doi:10.1124/jpet.115.226894
131. Vikram A, Kim Y, Kumar S, Li Q, Kassan M, Jacobs JS, et al. Vascular microRNA-204 is remotely governed by the microbiome and impairs endothelium-dependent vasorelaxation by downregulating sirtuin1. Nat Commun (2016) 7:12565. doi:10.1038/ncomms12565
132. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell (2008) 15:261-71. doi:10.1016/j.devcel.2008.07.002
133. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell (2008) 15:272-84. doi:10.1016/j.devcel.2008.07.008
134. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal (2009) 2:ra81. doi:10.1126/scisignal.2000610
135. Tang ST, Wang F, Shao M, Wang Y, Zhu HQ. MicroRNA-126 suppresses inflammation in endothelial cells under hyperglycemic conditions by targeting HMGB1. Vascul Pharmacol (2017) 88:48-55. doi:10.1016/j.vph.2016.12.002
136. Rawal S, Munasinghe PE, Shindikar A, Paulin J, Cameron V, Manning P, et al. Down-regulation of proangiogenic microRNA-126 and microRNA-132 are early modulators of diabetic cardiac microangiopathy. Cardiovasc Res (2017) 113:90-101. doi:10.1093/cvr/cvw235
137. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res (2010) 107:810-7. doi:10.1161/CIRCRESAHA.110.226357
138. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res (2010) 107:677-84. doi:10.1161/CIRCRESAHA.109.215566
139. Wang HW, Su SH, Wang YL, Chang ST, Liao KH, Lo HH, et al. MicroRNA-134 contributes to glucose-induced endothelial cell dysfunction and this effect can be reversed by far-infrared irradiation. PLoS One (2016) 11:e0147067. doi:10.137/journal.pone.0147067
140. Xu Q, Meng S, Liu B, Li MQ, Li Y, Fang L, et al. MicroRNA-130a regulates autophagy of endothelial progenitor cells through Runx3. Clin Exp Pharmacol Physiol (2014) 41:351-7. doi:10.1111/1440-1681.12227
141. Maegdefessel L, Rayner KJ, Leeper NJ. MicroRNA regulation of vascular smooth muscle function and phenotype: early career committee contribution. Arterioscler Thromb Vasc Biol (2015) 35:2-6. doi:10.1161/ATVBAHA.114.304877
142. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, et al. MiR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature (2009) 460:705-10. doi:10.1038/nature08195
143. Reddy MA, Das S, Zhuo C, Jin W, Wang M, Lanting L, et al. Regulation of vascular smooth muscle cell dysfunction under diabetic conditions by MIR-504. Arterioscler Thromb Vasc Biol (2016) 36:864-73. doi:10.1161/ATVBAHA.115.306770
144. Yang J, Chen L, Ding J, Fan Z, Li S, Wu H, et al. MicroRNA-24 inhibits high glucose-induced vascular smooth muscle cell proliferation and migration by targeting HMGB1. Gene (2016) 586:268-73. doi:10.1016/j.gene.2016.04.027
145. Kurtz CL, Peck BCE, Fannin EE, Beysen C, Miao J, Landstreet SR, et al. MicroRNA-29 finetunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes. Diabetes (2014) 63:3141-8. doi:10.2337/db13-1015
146. Wei S, Zhang M, Yu Y, Xue H, Lan X, Liu S, et al. HNF-4a regulated miR-122 contributes to development of gluconeogenesis and lipid metabolism disorders in type 2 diabetic mice and in palmitate treated HepG2 cells. Eur J Pharmacol (2016) 791:254-63. doi:10.1016/j.ejphar.2016.08.038
147. Fu X, Dong B, Tian Y, Lefebvre P, Meng Z, Wang X, et al. MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids. J Clin Invest (2015) 125:2497-509. doi:10.1172/JCI75438
148. Grove EL, Gregersen S. Antiplatelet therapy in patients with diabetes mellitus. Curr Vasc Pharmacol (2012) 10:494-505. doi:10.2174/157016112800812818
149. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol (2009) 16:961-6. doi:10.1038/nsmb.1651
150. Bray PF, McKenzie SE, Edelstein LC, Nagalla S, Delgrosso K, Ertel A, et al. The complex transcriptional landscape of the anucleate human platelet. BMC Genomics (2013) 14:1. doi:10.1186/1471-2164-14-1
151. Iaconetti C, Sorrentino S, De Rosa S, IndolfiC. Exosomal miRNAs in heart disease. Physiology (Bethesda) (2016) 31:16-24. doi:10.1152/physiol.00029.2015
152. Duan X, Zhan Q, Song B, Zeng S, Zhou J, Long Y, et al. Detection of platelet microRNA expression in patients with diabetes mellitus with or without ischemic stroke. J Diabetes Complications (2014) 28:705-10. doi:10.1016/j.diacomp.2014
153. Elgheznawy A, Shi L, Hu J, Wittig I, Laban H, Pircher J, et al. Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes. Circ Res (2015) 117:157-65. doi:10.1161/CIRCRESAHA.117.305784
154. Carino A, De Rosa S, Sorrentino S, Polimeni A, Sabatino J, Caiazzo G, et al. Modulation of circulating microRNAs levels during the switch from clopidogrel to ticagrelor. Biomed Res Int (2016) 2016:3968206. doi:10.1155/2016/3968206
155. Lugli G, Larson J, Martone ME, Jones Y, Smalheiser NR. Dicer and eIF2c are enriched at postsynaptic densities in adult mouse brain and are modified by neuronal activity in a calpain-dependent manner. J Neurochem (2005) 94:896-905. doi:10.1111/j.1471-4159.2005.03224.x
156. Fejes Z, Póliska S, Czimmerer Z, Káplár M, Penyige A, Gál Szabó G, et al. Hyperglycemia suppresses microRNA expression in platelets to increase P2RY12 and SELP levels in type 2 diabetes mellitus. Thromb Haemost (2017) 117:529-42. doi:10.1160/TH16-04-0322
157. Shi R, Zhou X, Ji WJ, Zhang YY, Ma YQ, Zhang JQ, et al. The emerging role of miR-223 in platelet reactivity: implications in antiplatelet therapy. Biomed Res Int (2015) 2015:981841. doi:10.1155/2015/98184
158. Zhang YY, Zhou X, Ji WJ, Shi R, Lu RY, Li JL, et al. Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. J Thromb Thrombolysis (2014) 38:65-72. doi:10.1016/j.thromres.2013.02.015
159. Luo M, Li R, Deng X, Ren M, Chen N, Zeng M, et al. Platelet-derived miR-103b as a novel biomarker for the early diagnosis of type 2 diabetes. Acta Diabetol (2015) 52:943-9. doi:10.1007/s00592-015-0733-0
160. Mills CD. M1 and M2 macrophages: oracles of health and disease. Crit Rev Immunol (2012) 32:463-88. doi:10.1615/CritRevImmunol.v32.i6.10
161. Stoger L, Gijbels MJ, van der Velden S, Manca M, van der Loos CM, Biessen EA, et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis (2012) 225:461-8. doi:10.1016/j.atherosclerosis.2012.09.013
162. Sun X, Lin J, Zhang Y, Kang S, Belkin N, Waea AK, et al. MicroRNA-181b improves glucose homeostasis and insulin sensitivity by regulating endothelial function in white adipose tissue. Circ Res (2016) 118:810-21. doi:10.1161/CIRCRESAHA.115.308166
163. Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet (2011) 4:446-54. doi:10.1161/CIRCGENETICS.110.958975
164. de Golzalo-Calvo D, van der Meer RW, Rijzewijk LJ, Smit JW, Revuelta-Lopez E, Nasarre L, et al. Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes. Sci Rep (2017) 7:47. doi:10.1038/s41598-017-00070-6
165. Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med (2007) 13:613-8. doi:10.1038/nm1582
166. Shan YX, Liu TJ, Su HF, Samsamshariat A, Mestril R, Wang PH. Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells. J Mol Cell Cardiol (2003) 35:1135-43. doi:10.1016/S0022-2828(03)00229-3
167. Rawal S, Manning P, Katare R. Cardiovascular microRNAs: as modulators and diagnostic biomarkers of diabetic heart disease. Cardiovasc Diabetol (2014) 13:44. doi:10.1186/1475-2840-13-44
168. Nandi SS, Zheng H, Sharma NM, Shahshahan HR, Patel KP, Mishra PK. Lack of miR-113a decreases contractility of diabetic hearts: a role for novel cross talk between tyrosine aminotransferase and tyrosine hydroxylase. Diabetes (2016) 65:3075-90. doi:10.2337/db16-0023
169. De Rosa R, De Rosa S, Leistner D, Boeckel JN, Keller T, Fichtlscherer S, et al. Transcoronary concentration gradient of microRNA-133a and outcome in patients with coronary artery disease. Am J Cardiol (2017) 120:15-24. doi:10.1016/j.amjcard.2017.03.264
170. Babiarz JE, Ravon M, Sridhar S, Ravindran P, Swanson B, Bitter H, et al. Determination of the human cardiomyocyte mRNA and miRNA differentiation network by fine-scale profiling. Stem Cells Dev (2012) 21:1956-65. doi:10.1089/scd.2011.0357
171. Wang JX, Jiao JQ, Li Q, Long B, Wang K, Liu JP, et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin related protein-1. Nat Med (2011) 17:71-8. doi:10.1038/nm.2282
172. Palmieri D, D'Angelo D, Valentino T, De Martino I, Ferraro A, Wierinckx A, et al. Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene (2012) 31:3857-65. doi:10.1038/onc.2011.557
173. Mussnich P, D'Angelo D, Leone D, Croce CM, Fusco A. The high mobility group A proteins contribute to thyroid transformation by regulation miR-603 and miR-10b expression. Mol Oncol (2013) 7:531-42. doi:10.1016/j.molonc.2013.01.002
174. Gareri C, Iaconetti C, Sorrentino S, Covello C, De Rosa S, IndolfiC. miR-125a-5p modulates phenotypic switch of vascular smooth muscle cells by targeting ETS-1. J Mol Biol (2017) 429:1817-28. doi:10.1016/j.jmb.2017.05.008
175. Lee JT. Epigenetic regulation by long noncoding RNAs. Science (2012) 338:1435-9. doi:10.1126/science.1231776
176. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet (2014) 15:7-21. doi:10.1038/nrg3606
177. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell (2011) 43:904-14. doi:10.1016/j.molcel.2011.08.018
178. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet (2011) 12:861-74. doi:10.1038/nrg3074
179. Elia L, Condorelli G. RNA (epi)genetics in cardiovascular diseases. J Mol Cell Cardiol (2015) 89:11-6. doi:10.1016/j.yjmcc.2015.07.012
180. Aryal B, Rotllan N, Fernández-Hernando C. Noncoding RNAs and atherosclerosis. Curr Atheroscler Rep (2014) 16:407. doi:10.1007/s11883-014-014-0407-3
181. Dechamethakun S, Muramatsu M. Long noncoding RNA variations in cardiometabolic diseases. J Hum Genet (2017) 62:97-104. doi:10.1038/jhg.2016.70
182. Carter G, Miladinovic B, Patel AA, Deland L, Mastorides S, Patel NA. Circulating long noncoding RNA GAS5 levels are correlated to prevalence of type 2 diabetes mellitus. BBA Clin (2015) 4:102-7. doi:10.1016/j.bbacli.2015.09.001
183. Li H, Zhu H, Ge J. Long noncoding RNA: recent updates in atherosclerosis. Int J Biol Sci (2017) 12:898-910. doi:10.7150/ijbs.14430
184. Kumarswamy R, Bauters C, Volkmann I, Maury F, Fetisch J, Holzmann A, et al. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res (2014) 114:1569-75. doi:10.1161/CIRCRESAHA.114.303915
185. Michalik KM, You X, Manavski Y, Doddaballapur A, Zornig M, Braun T, et al. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res (2014) 114:1389-97. doi:10.1161/CIRCRESAHA.114.303265
186. Liu JY, Yao J, Li XM, Song YC, Wang XQ, Li YJ, et al. Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus. Cell Death Dis (2014) 5:e1506. doi:10.1038/cddis.2014.466
187. Puthanveetil P, Chen S, Feng B, Gautam A, Chakrabarti S. Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells. J Cell Mol Med (2015) 19:1418-25. doi:10.1111/jcmm.12576
188. Li X, Wang H, Yao B, Xu W, Chen J, Zhou X. lncRNA H19/miR-675 axis regulates cardiomyocyte apoptosis by targeting VDAC1 in diabetic cardiomyopathy. Sci Rep (2016) 6:36340. doi:10.1038/srep36340
189. Reddy MA, Chen Z, Park JT, Wang M, Lanting L, Zhang Q, et al. Regulation of inflammatory phenotype in macrophages by a diabetes-induced long noncoding RNA. Diabetes (2014) 63:4249-61. doi:10.2337/db14-0298
190. Zgheib C, Hodges MM, Hu J, Liechty KW, Xu J. Long non-coding RNA Lethe regulates hyperglycemia-induced reactive oxygen species production in macrophages. PLoS One (2017) 12:e0177453. doi:10.1371/journal.pone.0177453